OncoMatch/Clinical Trials/NCT06420440
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Is NCT06420440 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Lenvatinib and Tislelizumab for hcc.
Treatment: Lenvatinib · Tislelizumab · Tislelizumab — Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC-A TUMOR DIAMETER MORE THAN OR EQUAL TO 5CM, BCLC-B, BCLC-C (BCLC)
Enhanced MRI determines that the tumor is technically resectable but at high risk for recurrence(BCLC-A tumor diameter more than or equal to 5cm; BCLC-B; BCLC-C) ; without distant metastasis.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Liver function
child-pugh liver function score ≤ 7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify